Avania Appoints Recognized CRO and MedTech Industry Leader, Jason Monteleone, as New President and CEO
4.9.2024 16:00:00 EEST | Business Wire | Press release
Avania — the leading global MedTech clinical research organization (CRO) providing product development, market access, and clinical contract research services — today announced the appointment of Jason Monteleone as president and CEO, effective September 2, 2024. Monteleone succeeds Sapna Hornyak, who had served as president and CEO since 2019. Under Hornyak’s leadership, Avania developed a strong, integrated global MedTech platform, which Jason will further enhance through growth initiatives, deeper therapeutic specialization, and innovation to solidify Avania’s position as a leading MedTech CRO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904978746/en/
Jason Monteleone, newly appointed president and CEO of Avania. (Photo: Business Wire)
With over 25 years of experience in the CRO, medical device, and life sciences sectors, Monteleone brings deep expertise in driving growth, innovation, and operational excellence. From 2017 until 2021, Monteleone was CEO of Clinipace, a global midsize CRO, where revenue increased 65% under his tenure before being acquired by dMed in April 2021. While chief financial officer at Theorem Clinical Research, a global midsize CRO focused on pharmaceutical and medical device studies, revenue and head count doubled before being acquired by Chiltern International in September 2015. Most recently, Monteleone served as president of Ancillare, a global provider of ancillary supplies and equipment for clinical trials.
Additionally, Monteleone is a board member and audit chair for the Drug Information Association (DIA), the leading global multidisciplinary life science membership association driving collaboration in drug, device, and diagnostic development in pursuit of a healthier world. Monteleone founded Pivotal Financial Consulting, advising investors and companies in clinical research on acquisitions, growth strategies, and innovation. He was also director of finance at VIASYS Healthcare, a publicly traded medical device company, before its acquisition by Cardinal Health and merger into CareFusion.
“I am honored to join Avania and lead this exceptional team at such an exciting time in our industry,” said Monteleone. “Avania partners with some of the world’s most innovative companies in numerous therapeutic areas such as cardiovascular, neurology, orthopedics, and aesthetics to name a few. The privilege to assist our customers in developing life-changing products for patients is the reason we are passionate about what we do, driving us to innovate, collaborate, and deliver excellence in every project.”
Todd Pope, chairman of Avania’s board, added, “I look forward to working closely with Jason as he leads Avania to continue making a positive impact for our customers, employees, and the MedTech community. The executive team and board are excited about the future as we bring Avania to the forefront of innovation and operational excellence.”
Edouard Pillot, partner and co-head of Astorg Mid-Cap, the majority shareholder in Avania, remarked, “We are excited to welcome Jason as Avania’s new CEO. His exceptional track record of driving growth and operational excellence, combined with his experience in scaling businesses, make him the perfect leader for Avania’s next phase. With deep expertise in the CRO and MedTech industries, Jason will drive innovation and deliver distinctive solutions for our customers. We look forward to seeing Avania create long-term value for its stakeholders under his leadership.”
About Avania
Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904978746/en/
Contacts
Holli Kroeker
+1 308-338-2358
pr@scorrmarketing.com
Jasmine Saba
+1 214 418 3201
jasmine.saba@avaniaclinical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify's Q2 Global Air Travel Fraud Report Finds Fraud Pressure Intensifying Across Middle East and Africa15.7.2026 14:00:00 EEST | Press release
Accertify, a leading fraud decisioning provider whose Predictive Yes Platform helps merchants say yes to more good customers, more revenue, and more growth, today announced the release of its Global Air Travel Fraud Report: Q2 2026, a quarterly analysis examining how fraud pressure varies across global airline markets based on departure city at time of booking. Based on analysis of 132.9 million airline booking transactions processed between April and June 2026, the report evaluates prevented fraud rates across 537 departure cities that each processed at least 10,000 transactions during the quarter, providing airlines with a data-driven view of where Accertify's Predictive Yes platform intervened most frequently at booking. The Q2 findings reveal that fraud pressure continues to vary significantly by market, with the most notable shift occurring across the Middle East and Africa. The region's average prevented fraud rate more than doubled quarter over quarter, from 0.95% to 2.03% — the
Forrester’s 2027 Budget Planning Guides: After A Year Of Caution, Business And Tech Leaders Are Ready To Invest Again15.7.2026 12:00:00 EEST | Press release
According to Forrester’s (Nasdaq: FORR) 2027 Budget Planning Guides, business and technology leaders are approaching 2027 with renewed confidence as they increasingly accept volatility as a permanent feature of the business environment. After a year of more cautious spending, more than 80% of leaders expect their budgets to increase over the next 12 months, with as many as one-quarter anticipating growth of 10% or more. But planning in the age of AI demands more than bigger budgets: Increasing investment without modernizing operating models, strengthening data foundations, and improving AI readiness will only accelerate fragmented data, duplicated work, and technical debt. To realize AI’s full potential, leaders must rethink their strategies and prioritize investments in operational foundations, governance, and experimentation that drive tangible outcomes. This year, optimism is widespread across functions: 82% of technology decision-makers and 91% of marketers expect budget increases
Post-Quantum’s Algorithm - Classic McEliece - Achieves Global ISO Standardization to Protect the World From Quantum Cyber Attack15.7.2026 11:00:00 EEST | Press release
It’s proven that today’s encryption is vulnerable to attack by a sufficiently mature quantum computer running Shor’s algorithm - a catastrophic event commonly known as Q-Day. Even before such a cryptographically relevant quantum computer emerges it is known that adversaries are stealing encrypted data now, which can be decrypted later - also known as Harvest Now, Decrypt Later (HNDL). Google’s recent use of Artificial Intelligence (AI) to optimise Shor’s algorithm reduces the number of physical qubits required to break today’s encryption, therefore shortening the timeline to Q-Day. This has led prominent experts to estimate today’s encryption may be broken as-soon-as the next three years. It’s against this backdrop that the International Organisation for Standardisation (ISO) has included the Classic McEliece algorithm as part of its standard for Asymmetric Ciphers (ISO/IEC 18033-2). Organisations from ISO’s 177 member states can now upgrade to Classic McEliece using an international s
Thredd Joins The Visa Agentic Ready Programme, Bringing Agent Network Readiness To Issuers Across Europe, Starting With Zilch15.7.2026 10:00:00 EEST | Press release
Thredd, the AI-first issuer processing platform, today announced it has joined the Visa Agentic Ready programme, enabling issuers across Europe to participate in agent-initiated payments without rebuilding their payments infrastructure. Consumer payments platform Zilch will be among the first issuers on the platform to enable agent-initiated payments for its cardholders. As a processor and enabler, Thredd sits at the trust layer of the payments ecosystem. By joining the programme, Thredd is ready to support Visa and its clients as the market moves into agentic commerce. Agentic commerce introduces a new type of payment initiator: An AI agent acting on a cardholder's behalf. The core payments principles do not change. Cardholder permission, issuer approval, authentication and fraud monitoring all still apply. What changes is how trust is established and enforced at the point an agent transacts. Taking a Zilch customer as an example, a cardholder might ask an AI agent to find a product w
Surgerii Robotics Announces First European Installation of the SHURUI ® Single-Port Surgical System at Vall d'Hebron University Hospital15.7.2026 10:00:00 EEST | Press release
Surgerii Robotics today announced the first European installation of its SHURUI Single-Port (SP) Surgical System at Vall d'Hebron University Hospital in Barcelona, Spain, one of Europe's leading academic medical centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713209503/en/ The first pediatric procedure performed with the SHURUI SP system was a nephroureterectomy on a twelve-year-old boy whose kidney and ureter had become infected and non-functional due to multiple stones. The SHURUI SP system is CE-marked for adult and pediatric use, making it the only CE-marked single-port robotic surgical system currently indicated for pediatric procedures in Europe. The installation marks an important milestone in the international expansion of Surgerii Robotics and the introduction of the technology into a major European reference center. As part of this collaboration, Vall d'Hebron University Hospital has become the first hos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom